Buy VRDN by Jul 20, 2026.

A lot of biotech is sitting in the sweet spot right now. I did really well riding REPL from around $3, and OTLK's been good to me from $0.8. The one I'd add to that list is AKBA around $1.04. It's smaller and a lot riskier, but the setup is genuinely asymmetric. I'd start small, maybe 0.5% NAV, and scale toward 1.5% as it plays out. Same lens I always use, market cap first. You're basically buying \~$230M of revenue …